 Marrone Bio Innovations Inc NASDAQ:MBII FRA:0MB shares climbed Friday after an analyst at Canaccord Genuity upped the price target for the company to 3.50 from 2 and reiterated a Buy rating. The company introduced a 2022 revenue projection of 7.7 million based on a continuing shift to seed and soil treatments and plant health solutions, with an EBITDA of 1.2 million. 